95.36
Corcept Therapeutics Inc stock is traded at $95.36, with a volume of 1.00M.
It is down -1.34% in the last 24 hours and up +16.92% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
See More
Previous Close:
$96.66
Open:
$96.76
24h Volume:
1.00M
Relative Volume:
0.90
Market Cap:
$10.24B
Revenue:
$769.10M
Net Income/Loss:
$46.67M
P/E Ratio:
272.46
EPS:
0.35
Net Cash Flow:
$119.79M
1W Performance:
+5.35%
1M Performance:
+16.92%
6M Performance:
+116.83%
1Y Performance:
+41.09%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CORT
Corcept Therapeutics Inc
|
95.36 | 10.24B | 769.10M | 46.67M | 119.79M | 0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-26 | Upgrade | UBS | Neutral → Buy |
| Mar-26-26 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept Therapeutics (CORT) Lifted Earnings Outlook, Is The Stock Now Overvalued? - Yahoo Finance UK
Corcept Therapeutics (CORT) Is Up 5.3% After Analysts Lift Full-Year Earnings Outlook Significantly - Yahoo Finance UK
Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CORT|Corcept Therapeutics Inc|Price:95.330|Chg%:-1.330 - TradingKey
Corcept Therapeutics Inc (CORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WDC: Western Digital Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Corcept Therapeutics Inc (CORT) Fundamental & Financial Data - Stocktwits
CORT: Corcept Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Corcept Therapeutics And 2 Other Growth Stocks With Significant Insider Ownership - simplywall.st
Corcept Therapeutics to announce Q2 results on July 29 - scanx.trade
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
Corcept Therapeutics stock hits 52-week high at 95.18 USD By Investing.com - Investing.com Canada
Trump Disclosure Shows Corcept Buy Before FDA Approval - Moomoo
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Corcept Therapeutics(CORT.US) Officer Sells US$3.51 Million in Common Stock - Moomoo
Corcept Therapeutics CFO Mokari sells $3.5m in shares By Investing.com - Investing.com South Africa
Corcept Therapeutics CFO Mokari sells $3.5m in shares - Investing.com
Corcept Therapeutics director Wilson sells $882,985 in common stock By Investing.com - Investing.com UK
Form 4 Corcept Therapeutics Incorporated For: 17 July By Investing.com - Investing.com Canada
Corcept Therapeutics (CORT) director logs 10,000-share indirect sale under 10b5-1 plan - Stock Titan
Corcept Therapeutics (CORT) CFO sells 40,000 shares and exercises options - Stock Titan
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook - Yahoo Finance
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook - The Motley Fool
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup - ChartMill
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Fed. Circ. Won't Rethink Corcept Patent Loss In Teva Case - Law360
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors - Seeking Alpha
Corcept Therapeutics : CORT - 24/7 Wall St.
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Form 4 Corcept Therapeutics Incorporated For: 8 July By Investing.com - Investing.com Nigeria
Corcept (NASDAQ: CORT) CBO reports 600-share stock gift and holdings - Stock Titan
Corcept Therapeutics CDO William Guyer sells $1.86m in stock - Investing.com
Corcept Therapeutics CDO William Guyer sells $1.86m in stock By Investing.com - Investing.com India
Insider at Corcept (NASDAQ: CORT) sells shares after option exercise - Stock Titan
Form 144 CORCEPT THERAPEUTICS INC For: 7 July By Investing.com - Investing.com Nigeria
William Guyer to sell 20,000 CORT shares (NASDAQ: CORT) via option exercise - Stock Titan
Corcept Therapeutics highlights its endocrine focus as investors watch CORT stock - AD HOC NEWS
CORT News | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept (CORT) executive sells 25K shares after exercising options - Stock Titan
CORTCorcept Therapeutics Inc Options - Finviz
Corcept Therapeutics stock hits 52-week high at 91.1 USD By Investing.com - Investing.com Canada
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report - Sahm
Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to book forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Wolfe Research Upgrades Corcept Therapeutics (CORT) to Peer Perf - GuruFocus
Enterprise value to revenue forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to earnings forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Corcept sinks after FDA rejects drug to treat hypertension - MSN
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index - marketscreener.com
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corcept Therapeutics Inc Stock (CORT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mokari Atabak | Chief Financial Officer |
Jul 15 '26 |
Option Exercise |
21.56 |
40,000 |
862,235 |
56,130 |
| Mokari Atabak | Chief Financial Officer |
Jul 15 '26 |
Sale |
87.71 |
40,000 |
3,508,277 |
16,130 |
| Guyer William | Chief Development Officer |
Jul 07 '26 |
Option Exercise |
21.65 |
20,000 |
433,000 |
23,985 |
| Guyer William | Chief Development Officer |
Jul 07 '26 |
Sale |
93.13 |
20,000 |
1,862,530 |
3,985 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):